Saxenda vs Wegovy: How the Daily and Weekly Shots Really Compare

If you have been offered Saxenda and you have seen the headlines about Wegovy, you probably want one number: how much better is the weekly shot? Unusually for this drug class, there is a direct answer from a trial that gave one group each drug and compared them. This article walks through that trial, then through the parts the trial does not cover — price, availability, side effects in real life, and the fact that the Saxenda brand is scheduled to disappear.

This is not medical advice. Where this article describes doses, escalation or stopping rules, it is summarizing the FDA-approved prescribing information and Instructions for Use; follow your own prescription and the directions your provider and pharmacist give you.

Quick terminology, because the brand names hide what is going on. Saxenda is liraglutide. Wegovy is semaglutide. Both are GLP-1 receptor agonists and both are made by Novo Nordisk, but they are two different molecules. Saxenda is injected once a day. Wegovy is injected once a week.

What is the actual difference in weight loss?

The trial is called STEP 8. It ran at 19 US sites, enrolled 338 adults with overweight or obesity and no diabetes, and ran for 68 weeks. Participants were randomized to weekly semaglutide 2.4 mg, daily liraglutide 3.0 mg, or placebo, and everyone got diet and physical activity counseling. It was published in JAMA in January 2022 [1][2].

The result:

Outcome at 68 weeks	Semaglutide 2.4 mg weekly	Liraglutide 3.0 mg daily	Placebo
Average weight change	−15.8%	−6.4%	−1.9%
Lost at least 10%	70.9%	25.6%	—
Lost at least 15%	55.6%	12.0%	—
Lost at least 20%	38.5%	6.0%	—
Stopped treatment for any reason	13.5%	27.6%	—
Had gastrointestinal side effects	84.1%	82.7%	—

The difference in average weight loss was 9.4 percentage points, with a 95% confidence interval of −12.0 to −6.8, and it was highly statistically significant [1]. For a person starting at 220 pounds, that gap is roughly 35 pounds versus roughly 14 pounds.

Two details in that table deserve more attention than they usually get.

First, the side effect rates were almost identical. Nausea, diarrhea, constipation and vomiting showed up in more than eight out of ten people in both groups. The common belief that liraglutide is “gentler because it is older and weaker” is not what this trial found.

Second, twice as many people quit liraglutide. More than one in four left the liraglutide arm before the end, against about one in seven on semaglutide. Part of that is the side effect burden landing every single day instead of once a week, and part is simply the grind of 365 injections a year versus 52.

Why is the weekly drug so much stronger?

It is not just the dosing interval. Semaglutide and liraglutide are structurally different peptides, and semaglutide was engineered for a much longer half-life and a higher effective exposure. Trials also escalate them differently: in STEP 8, the semaglutide group climbed over 16 weeks while the liraglutide group climbed over 4 weeks [1][3].

That fast four-week liraglutide climb is written into the Saxenda label: 0.6 mg in week one, 1.2 mg in week two, 1.8 mg in week three, 2.4 mg in week four, and 3 mg from week five onward [4]. Going up a step every seven days is why so many people describe the first month on Saxenda as relentless.

What do Saxenda’s own trials say?

Set the comparison aside for a moment. On its own terms, the Saxenda label reports three 56-week randomized placebo-controlled trials [4]:

• In adults with obesity or overweight plus a weight-related condition (2,487 on Saxenda versus 1,244 on placebo): average weight change −7.4% versus −3.0%. 62.3% versus 34.4% lost at least 5%. 33.9% versus 15.4% lost more than 10%.
• In adults with type 2 diabetes (423 versus 212): −5.4% versus −1.7%. Results were noticeably smaller in this group.
• In adults who had already lost at least 5% during a low-calorie run-in (212 versus 210): −4.9% versus +0.3% — that is, the placebo group regained slightly while the Saxenda group kept losing.

A 160-week extension in the subgroup with abnormal blood glucose found that 28% of Saxenda patients and 14% of placebo patients were known to have lost at least 5% at week 160 [4]. Weight loss faded over three years in both groups.

An independent Cochrane review published in October 2025 pooled 24 randomized trials and 9,937 participants. It concluded liraglutide “likely increases the proportion of people achieving at least 5% weight loss” with moderate certainty, but rated the evidence for percentage weight change as very low certainty and found increased adverse events, including serious ones. It also noted that 22 of the 24 trials were funded by the manufacturer [5].

What about side effects day to day?

The Saxenda label’s adverse reaction table, drawn from five placebo-controlled trials in 3,384 adults, shows the most common problems [4]:

Reaction	Saxenda	Placebo
Nausea	39.3%	13.8%
Diarrhea	20.9%	9.9%
Constipation	19.4%	8.5%
Vomiting	15.7%	3.9%
Injection site reaction	13.9%	10.5%
Headache	13.6%	12.6%
Low blood sugar in type 2 diabetes	12.6%	6.6%

About 10% of people on Saxenda stopped because of a side effect, versus 4% on placebo, and most of those exits happened in the first few months [4].

Both drugs carry the same class-level boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [4]. Both labels also warn about pancreatitis, gallbladder disease, kidney injury from dehydration, increased resting heart rate, and the risk of food or liquid entering the lungs during anesthesia.

One change worth knowing: in October 2025 a new warning about severe gastrointestinal reactions was added to the liraglutide labels, and the products are now described as not recommended for people with severe gastroparesis. In February 2026 the separate section on suicidal behavior and ideation was removed from the Saxenda label [4][6].

Which one costs less?

This is where the comparison flips.

Liraglutide is the only GLP-1 receptor agonist available as an FDA-approved generic in the United States — for both diabetes and weight management. Teva launched the first generic version of Saxenda in August 2025, and Cipla, Biocon and Orbicular products followed in early 2026 [7].

Checked on September 14, 2026, GoodRx listed generic liraglutide in the Saxenda-equivalent five-pen carton at a coupon price of $372.45 (verified 2026-09-14) against a $717.63 average retail price [8]. That $717.63 is GoodRx’s own average — it states “Save 48.10%”, which reconciles exactly — and not the price at any one pharmacy. Across pharmacies and ZIP codes the cash price for this carton spans roughly $372 to $1,240, so it is a range rather than a single number. A five-pen carton covers roughly a month at the 3 mg maintenance dose. For comparison, brand Saxenda’s manufacturer list price is $1,349.02 a month per NovoCare, and NovoCare’s “as little as $25” offer is a savings-card tier requiring commercial insurance that already covers Saxenda, not a self-pay price [12]. Those prices move daily and vary by pharmacy and location.

There is no generic Wegovy. Semaglutide remains under patent in the United States.

So the honest framing is: Wegovy buys roughly two and a half times the average weight loss; generic liraglutide buys a GLP-1 you can actually pay for out of pocket. Which trade is right depends on your insurance, your budget, and what your prescriber thinks is safe and sensible for you.

Is Saxenda going away?

The brand is. On August 25, 2026 the FDA’s drug discontinuation database recorded a Novo Nordisk notice for Saxenda stating that the product “will be available until discontinuation in January 2027,” with the reason given as discontinuation of the manufacture of the drug. The same database lists Saxenda’s availability as Limited in the meantime [6]. No matching press release appeared in Novo Nordisk’s US news archive as of September 14, 2026, so the January 2027 date should be read as coming from the FDA record rather than from a company announcement.

Generic liraglutide approved against Saxenda is a separate matter and remains marketed by several companies. That said, supply of the five-pen weight-management cartons was patchy in spring 2026: patients in the r/liraglutide community described being unable to fill them in May and June while the two-pen and three-pen diabetes cartons stayed available [9]. If you are on liraglutide 3 mg, it is worth asking your pharmacy to check stock before your refill week.

Can you switch from one to the other?

Switching is a prescriber decision, and this article cannot and will not tell you how to do it. What the labels say is useful context, though:

• The Saxenda label’s Limitations of Use state that coadministration with other liraglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. (The Victoza label’s Limitations of Use are narrower — they name only other liraglutide-containing products — so this is a Saxenda-label statement, not a shared one) [4][11].
• Wegovy has its own starting dose and its own escalation schedule. There is no official “equivalent dose” table that maps a liraglutide dose onto a semaglutide dose.
• The Saxenda prescribing information directs clinicians that when more than three days have elapsed since the last dose, treatment is reinitiated at 0.6 mg and re-escalated, to reduce gastrointestinal reactions on reinitiation. The patient-facing Medication Guide in the same label tells patients who have missed doses for three days or more to call their healthcare provider about how to restart, rather than restarting on their own [4]. Either way it says something useful about gaps in general: a pause is not neutral.

Bring the question to a healthcare provider, along with your insurance formulary, because in practice coverage often decides this more than clinical preference does.

What about teenagers?

Saxenda is labeled for people aged 12 and older who weigh more than 60 kg and have obesity. The evidence is SCALE Teens, a 56-week randomized double-blind trial in 251 adolescents aged 12 to under 18 who had not responded to lifestyle therapy alone. Liraglutide reduced the BMI standard-deviation score by an estimated 0.22 more than placebo. 43.3% of the liraglutide group achieved at least a 5% BMI reduction versus 18.7% on placebo. Gastrointestinal side effects hit 64.8% versus 36.5%, and 10.4% of the liraglutide group stopped because of a side effect versus none on placebo. After treatment ended, BMI rose more in the liraglutide group than in the placebo group [10].

The Saxenda label also includes a specific checkpoint for young people: evaluate BMI after 12 weeks on the maintenance dose and stop if BMI has not fallen by at least 1% from baseline [4]. For adults the equivalent rule is 16 weeks and 4% of body weight.

The short version

Wegovy wins on effectiveness by a wide, trial-proven margin. Saxenda and its generics win on price and on being available as a substitutable generic at all. Side effect rates in the head-to-head trial were essentially the same; the difference was that far more people gave up on the daily shot. And the Saxenda brand itself is on the way out, with generics carrying the molecule forward.

None of that decides anything for you. Bring both the STEP 8 numbers and your actual pharmacy price to a healthcare provider and make the call together.

Sources

1. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, January 2022
2. STEP 8 — PubMed record, PMID 35015037
3. NCT04074161 — STEP 8 registry entry, ClinicalTrials.gov
4. SAXENDA (liraglutide) injection, solution — prescribing information, DailyMed, updated 2026-02-25
5. Meza N et al. Liraglutide for adults living with obesity. Cochrane Database of Systematic Reviews, 2025-10-30
6. FDA Drug Shortages — Liraglutide Injection, discontinuation record
7. Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection), 2025-08-28
8. Liraglutide (Saxenda) prices — GoodRx, retrieved 2026-09-14
9. r/liraglutide — “U.S. Generic Saxenda Shortage Is Bad”, 2026-05-27
10. Kelly AS et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. New England Journal of Medicine, 2020
11. VICTOZA (liraglutide) injection — prescribing information, DailyMed, SPL version dated 2025-10-14
12. Saxenda (liraglutide) injection 3 mg list price explained — NovoCare, Novo Nordisk, retrieved 2026-09-14